Proqr Therapeutics (PRQR) Stock Price, Quote & News

Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Re...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 88 166 7000

Website: www.proqr.com

Address:

Zernikedreef 9, Leiden, Netherlands

Geert07 Feb. 12 at 6:21 PM

$PRQR I started adding small batches between 1.60 and 1.35. Let’s see how far it will drop.

1 · Reply

ehpats Feb. 12 at 2:13 PM

$PRQR wonder if we will get preliminary data on the additional cohorts? Seem like that data should be known by late February.

1 · Reply

dirkfrank Feb. 12 at 3:51 AM

$PRQR pffff jeez

0 · Reply

RandomInvestor777 Feb. 9 at 7:23 PM

$PRQR Board changes. probably to get van herk off their backs... except it's not the ones van herk named.... well its progress at least https://www.proqr.com/press-releases/proqr-announces-planned-changes-to-board-composition

2 · Reply

biochirp Feb. 9 at 4:12 PM

$PRQR $LLY just bought another early stage biotech for billions Market cap here is way too low

1 · Reply

dirkfrank Feb. 9 at 2:12 PM

$PRQR Valerio and Lawton are leaving the board as planned. Who will come to replace them? Van Herk’s peeps…

2 · Reply

Kyle7776 Feb. 8 at 9:13 PM

$PRQR baker bros and point72 are more votes of confidence than van herk to be honest and both didnt invest yet

0 · Reply

Benitocalixto Feb. 7 at 3:34 PM

$PRQR Amended Schedule 13D indicating Van Herk beneficial ownership of 15,384,250 ordinary shares, representing about 14.6% of ProQR’s ordinary shares..

1 · Reply

HeartOfTheCrow Feb. 7 at 1:53 AM

$PRQR Van Herk scooped another 1m shares over the past few months

2 · Reply

johnnygogogo Feb. 6 at 2:18 PM

$PRQR who wants to buy up the whole float today?

1 · Reply

ProQR Announces Planned Changes to Board Composition

Jan 8, 2026, 8:00 AM EST - 5 weeks ago

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

Dec 1, 2025, 8:00 AM EST - 2 months ago

ProQR to Participate in 8th Annual Evercore Healthcare Conference

Nov 6, 2025, 7:00 AM EST - 3 months ago

ProQR Announces Third Quarter 2025 Operating and Financial Results

Nov 3, 2025, 6:46 PM EST - 3 months ago

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

Oct 20, 2025, 8:00 AM EDT - 4 months ago

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

Oct 13, 2025, 8:30 AM EDT - 4 months ago

ProQR to Participate in Upcoming Investor Conferences in October 2025

Aug 7, 2025, 7:00 AM EDT - 6 months ago

ProQR Announces Second Quarter 2025 Operating and Financial Results

Jul 28, 2025, 8:00 AM EDT - 7 months ago

ProQR Announces Upcoming Presentation at RNA Editing Summit

Jun 26, 2025, 4:30 PM EDT - 8 months ago

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

May 12, 2025, 8:00 AM EDT - 10 months ago

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 8, 2025, 7:00 AM EDT - 10 months ago

ProQR Announces First Quarter 2025 Operating and Financial Results

May 2, 2025, 8:00 AM EDT - 10 months ago

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

May 1, 2025, 8:00 AM EDT - 10 months ago

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

Apr 14, 2025, 7:00 AM EDT - 11 months ago

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

Mar 13, 2025, 7:00 AM EDT - 1 year ago

ProQR Announces Year End 2024 Operating and Financial Results

Dec 10, 2024, 8:00 AM EST - 1 year ago

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

Oct 25, 2024, 4:45 PM EDT - 1 year ago

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 10:15 PM EDT - 1 year ago

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 4:01 PM EDT - 1 year ago

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Oct 7, 2024, 8:00 AM EDT - 1 year ago

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Sep 10, 2024, 4:30 PM EDT - 1 year ago

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

May 11, 2024, 5:57 PM EDT - 1 year ago

ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)

May 9, 2024, 7:00 AM EDT - 1 year ago

ProQR Announces First Quarter 2024 Operating and Financial Results

Apr 23, 2024, 7:00 AM EDT - 1 year ago

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

Apr 22, 2024, 4:31 PM EDT - 1 year ago

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

Apr 19, 2024, 7:00 AM EDT - 1 year ago

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Mar 13, 2024, 7:00 AM EDT - 2 years ago

ProQR Announces Year End 2023 Operating and Financial Results

Jan 19, 2024, 7:00 AM EST - 2 years ago

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Jan 5, 2024, 7:00 AM EST - 2 years ago

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

Dec 8, 2023, 7:30 AM EST - 2 years ago

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Nov 7, 2023, 7:00 AM EST - 2 years ago

ProQR Announces Third Quarter 2023 Operating and Financial Results

Nov 6, 2023, 7:00 AM EST - 2 years ago

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Sep 28, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

Sep 7, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 7:00 AM EDT - 2 years ago

ProQR Announces Second Quarter 2023 Operating and Financial Results

Aug 1, 2023, 7:00 AM EDT - 2 years ago

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets

Jul 9, 2023, 6:53 AM EDT - 2 years ago

ProQR: Too Many Failures For Its RNA Technology

Jul 6, 2023, 7:00 AM EDT - 2 years ago

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

May 9, 2023, 8:00 AM EDT - 3 years ago

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

Apr 20, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Upcoming Investor Conferences in April and May

Apr 18, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

Mar 29, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

Mar 14, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

Mar 7, 2023, 8:00 AM EST - 3 years ago

ProQR to Present at Upcoming Scientific and Industry Conferences

Dec 22, 2022, 9:12 AM EST - 3 years ago

ProQR's stock jumps on expanded RNA deal with Lilly

LLY

Dec 22, 2022, 6:15 AM EST - 3 years ago

ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

Dec 22, 2022, 6:00 AM EST - 3 years ago

Lilly and ProQR to Expand RNA Editing Collaboration

LLY

Nov 14, 2022, 4:30 PM EST - 3 years ago

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022

Nov 9, 2022, 7:00 AM EST - 3 years ago

ProQR Announces Third Quarter 2022 Operating and Financial Results

Geert07 Feb. 12 at 6:21 PM

$PRQR I started adding small batches between 1.60 and 1.35. Let’s see how far it will drop.

1 · Reply

ehpats Feb. 12 at 2:13 PM

$PRQR wonder if we will get preliminary data on the additional cohorts? Seem like that data should be known by late February.

1 · Reply

dirkfrank Feb. 12 at 3:51 AM

$PRQR pffff jeez

0 · Reply

RandomInvestor777 Feb. 9 at 7:23 PM

2 · Reply

biochirp Feb. 9 at 4:12 PM

$PRQR $LLY just bought another early stage biotech for billions Market cap here is way too low

1 · Reply

dirkfrank Feb. 9 at 2:12 PM

$PRQR Valerio and Lawton are leaving the board as planned. Who will come to replace them? Van Herk’s peeps…

2 · Reply

Kyle7776 Feb. 8 at 9:13 PM

$PRQR baker bros and point72 are more votes of confidence than van herk to be honest and both didnt invest yet

0 · Reply

Benitocalixto Feb. 7 at 3:34 PM

$PRQR Amended Schedule 13D indicating Van Herk beneficial ownership of 15,384,250 ordinary shares, representing about 14.6% of ProQR’s ordinary shares..

1 · Reply

HeartOfTheCrow Feb. 7 at 1:53 AM

$PRQR Van Herk scooped another 1m shares over the past few months

2 · Reply

johnnygogogo Feb. 6 at 2:18 PM

$PRQR who wants to buy up the whole float today?

1 · Reply

FutureInvesting777 Feb. 5 at 7:59 PM

$PRQR Ahh! Will gaps be closed? It remains to be seen.

1 · Reply

justfacts1 Feb. 4 at 9:20 PM

$PRQR hopefully they announce milestones with Lilly soon.

0 · Reply

Aciputes Feb. 4 at 10:40 AM

$PRQR What's happening in the premarket. Large volume before opening. Any news?

2 · Reply

Bionco Feb. 3 at 1:43 PM

$PRQR I am gradually accumulating at current level.....

1 · Reply

dirkfrank Feb. 2 at 10:48 PM

$PRQR

0 · Reply

ehpats Feb. 2 at 9:27 PM

$PRQR pps is concerning. Doesn’t anyone else see the opportunity here? Guess not.

1 · Reply

justfacts1 Feb. 2 at 8:59 PM

$PRQR we might see year 25 lows

0 · Reply

OfficialStocktwitsUser Feb. 2 at 3:49 PM

$PRQR RSI: 45.79, MACD: -0.1180 Vol: 0.18, MA20: 1.75, MA50: 1.99 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Kyle7776 Feb. 1 at 8:46 AM

$PRQR there will be no buyout. Eli lily gave those milestones for a reason. Howver if you wait you can 2x-5x from target engagement data in late Q2

2 · Reply

ACH50 Jan. 30 at 3:54 AM

$PRQR UBS Group AG significantly increased its stake in ProQR Therapeutics (PRQR) during Q4 2025, holding 797,664 shares as of December 31, 2025 (a 743.64% increase from the prior quarter). The 13F filing disclosing this was dated January 29, 2026.

2 · Reply

biochirp Jan. 28 at 8:33 PM

$PRQR Lily BD team has been very busy, few deals already announced this month. Giving PRQR 4-6 months then I’m out

1 · Reply

KostasBars Jan. 28 at 1:26 PM

$PRQR Get ready, there is something going on.

1 · Reply

Market Cap	153.61M
Revenue (ttm)	20.46M
Net Income (ttm)	-30.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-146.82%
Debt to Equity Ratio	0.08

Volume	354,900
Avg Vol	557,296
Day's Range	N/A - N/A
Shares Out	105.21M
Stochastic %K	46%
Beta	0.20
Analysts	Strong Sell
Price Target	$8.88